PMA supplement
P160045 S034: Oncomine Dx Target Test
FDA PMA supplement · Normal 180 Day Track No User Fee · Life Technologies Corporation
Key facts
| Original PMA | P160045 |
|---|---|
| Supplement number | S034 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Postapproval Study Protocol |
| Trade name | Oncomine Dx Target Test |
| Generic name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Life Technologies Corporation |
| Product code | PQP |
| Received date | Dec 23, 2021 |
| Decision date | Jan 21, 2022 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: